FDA Extends Holds in Immunotherapy Trials in Blood Cancers – Medscape
Medscape |
FDA Extends Holds in Immunotherapy Trials in Blood Cancers
Medscape Because of safety concerns, the US Food and Drug Administration has placed full or partial holds on clinical trials of three immunotherapies — pembrolizumab (Keytruda, Merck), nivolumab (Opdivo, BMS), and durvalumab (Imfinzi, AstraZeneca) — that are … |
